leisure time -WSS

leisure time

author：fashion 2025-10-01 00:06:35 - browse：143

Novo Nordisk Denmark — LISELOTTE SABROE/AFP/Getty Images

A pill being developed by Danish drugmaker Novo Nordisk may lead to greater weight loss than the obesity therapy Wegovy, the company reported Thursday, citing early data.

In a Phase 1 trial, participants experienced an average of 13.1% weight loss after 12 weeks of taking the experimental oral medicine amycretin, according to data presented at an investor meeting. In comparison, in an earlier Phase 3 trial of the injectable drug Wegovy, people taking Wegovy lost about 6% of their body weight over the same time period.

Novo Nordisk has been on a mission to capitalize on its success with Wegovy, which brought in $4.5 billion in sales last year. (The drug is also sold as a diabetes treatment under the name Ozempic. That version of the drug brought in another $14 billion in sales).

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Medicare Advantage enrollment hits roughly 33.4 million

explore

Wikipedia

WSS

Measles policy set amid Florida outbreak alarms vaccine proponents

More hospitals are billing patients as online messages surge

FDA warns medical device makers about rise in fabricated data

Surprise medical billing ban raises prices elsewhere

FDA warns medical device makers about rise in fabricated data

Medicare Advantage enrollment grows 7.1% to 33.4 million people

knowledge

leisure time

explore

Medical records are filled with copy

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

George Santos makes 1st court appearance after pleading not guilty to 13 counts

In 'major milestone,' FDA approves first cell therapy for solid tumors

After affirmative action ruling, medical educators look to 'holistic review'

New CMS data security rules will hurt Medicare, Medicaid research

Drug repurposing or repositioning? The language matters

Study: Hearing aids may slow cognitive decline in those at risk

Guidelines to prevent youth baseball injuries need more muscle

Researchers tackle phage therapy hurdles for wider adoption

entertainment

Flagship, Pfizer team up in deal worth up to $7 billion

Israeli protesters block highways, train stations as Netanyahu moves ahead with judicial overhaul

Ford plant in Missouri shuts down over 'possible threat,' sheriff's office says

Biden administration sends mixed signals on US soldier who crossed into North Korea

Hospitals are piloting generative AI tools as regulators play catch

Secretariat’s lessons for human medicine

explore

Wikipedia

focus

hotspot